Search clinical trials for: Licensed mRNA vaccine

Total 6891 results

AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
CureVac

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Rabies

Belgium, Germany
ModernaTX, Inc.

Recruiting

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

SARS-CoV-2

Australia
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
National Institute of Allergy and Infectious Diseases...
PPD

Completed

COVID-19 Protection After Transplant Pilot Study (CPAT)

Kidney Transplant Recipients

United States
Tan Tock Seng Hospital
KK Women's and Children's Hospital; Duke-NUS Graduate Medical School; A*Star

Recruiting

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PRIBIVAC)

COVID-19

Singapore
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Seasonal Influenza

United States
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
Sheba Medical Center
ModernaTX, Inc.

Completed

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults (SH-MO-214)

COVID-19 | SARS CoV 2 Infection | COVID-19 Pandemic | Immunogenicity

Israel
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Infections, Meningococcal

Germany, Canada, Australia, Belgium, Italy
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
Seqirus

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults

Influenza, Human

Australia
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
GlaxoSmithKline

Active, not recruiting

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

COVID-19

United States
Karolinska University Hospital
Karolinska Institutet

Active, not recruiting

COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (COVAXID)

Covid19

Sweden
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
International AIDS Vaccine Initiative
Emory University; Fred Hutchinson Cancer Center; George Washington University; ModernaTX... and other collaborators

Active, not recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Hiv

United States
Methodist Health System

Completed

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

COVID-19 | COVID-19 Pneumonia

United States
Mahidol University
World Health Organization; The Government Pharmaceutical Organization

Completed

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Influenza

Thailand
ModernaTX, Inc.

Completed

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
Duke University
Washington University School of Medicine; University of Pittsburgh; Centers for... and other collaborators

Active, not recruiting

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

COVID-19 | Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
University of Florida

Suspended

Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy

Melanoma

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)

COVID-19

United States, Australia, Brazil, Honduras
Sunnybrook Health Sciences Centre
University Health Network, Toronto; Unity Health Toronto; Scarborough General... and other collaborators

Terminated

COVID-19 Vaccine Boosters in Patients With CKD (BOOST KIDNEY)

COVID-19 | Chronic Kidney Diseases

Canada
University of Michigan
The Wallace Foundation

Recruiting

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

COVID-19 | Corona Virus Infection

United States
The University of Hong Kong

Active, not recruiting

Community-based Sero-epidemiological Study of COVID-19

COVID-19

Hong Kong
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | COVID-19 Infection

United States
University of Florida
University of California, San Francisco; Florida Department of Health; Pacific... and other collaborators

Recruiting

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PNOC020)

Adult Glioblastoma

United States
University of Melbourne

Completed

Influenza Vaccine in HIV Study

Influenza, Human
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Mahidol University
The Government Pharmaceutical Organization

Recruiting

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly

Influenza

Thailand
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Dengue Fever

Thailand
YueJuan Cheng
NeoCura

Recruiting

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors

Solid Tumor

China
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.

Not yet recruiting

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

SARS-CoV-2
University of Liege
Pfizer

Recruiting

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

Coronavirus Disease 2019 (Covid19) | Hematopoietic Neoplasms

Belgium
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

HIV Infections

United States, Canada
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Respiratory Syncytial Virus Infections

United States, Belgium, Netherlands, Spain
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Influenza | SARS-CoV-2

United States
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

SARS-CoV-2

China
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
National Institute of Allergy and Infectious Diseases...

Completed

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Covid19 | SARS-CoV2 Infection

United States

3

Subscribe